Krystal Biotech, Inc. (BIT:1KRYS)

Krystal Biotech Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	359.21	290.52	50.7	-	-	-
Revenue Growth (YoY)	116.09%	473.02%	-	-	-	-
Cost of Revenue	23.83	20.06	3.09	-	-	-
Gross Profit	335.38	270.45	47.61	-	-	-
Selling, General & Admin	127.89	113.69	98.4	77.74	40.39	15.06
Research & Development	55.7	53.57	46.43	42.46	27.88	17.94
Other Operating Expenses	-	37.5	12.5	25	-	-
Operating Income	151.8	65.7	-109.73	-145.2	-68.28	-33
Interest Income	29.45	29.66	22.62	5.22	0.2	0.83
Interest Expense	-	-	-	-	-1.49	-
Other Non-Operating Income (Expense)	-	-	100	-	-	-
Total Non-Operating Income (Expense)	29.45	29.66	122.62	5.22	-1.3	0.83
Pretax Income	168.75	95.36	12.9	-139.98	-69.57	-32.17
Provision for Income Taxes	22.03	6.2	1.97	-	-	-
Net Income	146.73	89.16	10.93	-139.98	-69.57	-32.17
Net Income to Common	146.73	89.16	10.93	-139.98	-69.57	-32.17
Net Income Growth	38.50%	715.58%	-	-	-	-
Shares Outstanding (Basic)	29	29	27	25	22	19
Shares Outstanding (Diluted)	30	30	28	25	22	19
Shares Change (YoY)	1.77%	7.16%	8.87%	14.85%	18.15%	18.15%
EPS (Basic)	5.12	3.12	0.40	-5.49	-3.13	-1.71
EPS (Diluted)	4.93	3.00	0.39	-5.49	-3.13	-1.71
EPS Growth	24.50%	669.23%	-	-	-	-
Free Cash Flow	185.44	119.18	-100.6	-153.55	-116.27	-40.93
Free Cash Flow Growth	55.60%	-	-	-	-	-
Free Cash Flow Per Share	6.20	4.01	-3.63	-6.02	-5.24	-2.18
Gross Margin	93.37%	93.09%	93.90%	-	-	-
Operating Margin	42.26%	22.61%	-216.43%	-	-	-
Profit Margin	40.85%	30.69%	21.56%	-	-	-
FCF Margin	51.63%	41.02%	-198.43%	-	-	-
EBITDA	158.06	72.41	-103.82	-141.81	-65.51	-31.15
EBITDA Margin	44.00%	24.92%	-204.77%	-	-	-
EBIT	151.8	65.7	-109.73	-145.2	-68.28	-33
EBIT Margin	42.26%	22.61%	-216.43%	-	-	-
Effective Tax Rate	13.05%	6.50%	15.24%	0.00%	0.00%	0.00%

Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.